Video

Receiving Molecular Testing Results for NSCLC

Author(s):

Benjamin Levy, MD,Bhuvana Ramkumar, MD

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity
View More
Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer
Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity
View More
(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
Video

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

May 15th 2025 - May 16th 2026

online-activity
View More
Related Content
The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.
May 17th 2025

The OncFive: Top Oncology Articles for the Week of 5/11

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC | Image Credit: © Karsyarina – stock.adobe.com
May 16th 2025

European Commission Approves Perioperative Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Advanced NSCLC | Image Credit: © catalin – stock.adobe.com
May 15th 2025

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC

Joshua K. Sabari, MD
May 15th 2025

Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting